Clinical trials: Recurrent Tumor
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, paclitaxel, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00310011
- Testing
- cisplatin, gemcitabine hydrochloride, paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 71 people
- Sponsor
- Wake Forest University Health Sciences
Leukemia, Myelodysplastic Syndromes
Evaluating Cell Damage in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Fanconi Anemia; in Patients Who Were Exposed to Alkylating Agents; and in Healthy Volunteers
RATIONALE: Studying samples of bone marrow from patients with cancer and from healthy volunteers in the laboratory may help doctors learn more about changes that occur in bone marrow stromal (connective tissue) cells.
- Trial name
- NCT00899795
- Testing
- cytogenetic analysis, fluorescence in situ hybridization, flow cytometry
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- OHSU Knight Cancer Institute
Perianal Fistula
FiLaC and PRGF-Endoret for Multi-recurrent Cryptoglandular Perianal Fistula (PLASMA Pilot Study)
Multi-recurrent cryptoglandular perianal fistula represents a challenging clinical problem with no established surgical solution after repeated failures.
- Trial name
- PLASMA (NCT07810075)
- Testing
- Laser ablation of fistula tract using 1000-µm radial fibre (Biolitec, 1470 nm, 12 W, continuous, 1 mm/s withdrawal). Internal opening closed with Vicryl 2/0 suture in all patients
- Volunteers
- 25 people
- Sponsor
- Complejo Hospitalario Universitario de Santiago
Head Neck Cancer
Medpulser Electroporation With Bleomycin Study to Treat Posterior Head and Neck Squamous Cell Carcinoma
The purpose of the study is to evaluate Medpulser electroporation (EPT) with bleomycin with regard to local tumor recurrence, disease-free survival, and overall survival rates versus surgery in recurrent or secondary primary…
- Trial name
- NCT00198328
- Testing
- Medpulser Electroporation with Bleomycin, Surgical Excision
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Inovio Pharmaceuticals
Glioblastoma, Adult, EGFR Amplification
GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification
This study is a phase 2 trial of GC1118, an EGFR monoclonal antibody, for recurrent glioblastoma patients who were treated with standard concurrent chemoradiation.
- Trial name
- NCT03618667
- Testing
- GC1118
- Where
- South Korea
- Volunteers
- 13 people
- Sponsor
- Samsung Medical Center
Advanced Malignant Mesothelioma, Recurrent Malignant Mesothelioma
Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma
This phase II trial is studying how well sunitinib works in treating patients with advanced malignant mesothelioma of the pleura.
- Trial name
- NCT00392444
- Testing
- sunitinib malate
- Where
- Canada
- Volunteers
- 39 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma
Combination Chemotherapy Plus Sargramostim in Treating Patients With Cancer of the Uterus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow…
- Trial name
- NCT00033644
- Testing
- sargramostim, cisplatin, dacarbazine
- Where
- 21 sites in United States, Norway
- Sponsor
- Gynecologic Oncology Group
Bladder Cancer
Treatment of Recurrent Bladder Cancer With Dendritic Cells
Treatment of recurrent bladder cancer with dendritic cells
- Trial name
- NCT04184232
- Testing
- Dendritic cells, Standard treatment according to the Clinical protocols
- Where
- Belarus
- Volunteers
- 17 people
- Sponsor
- Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Peripheral T-Cell Lymphoma
Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30
The main purpose of this study is to test if brentuximab vedotin has an effect on cancer in patients with a certain type of large B-cell lymphoma.
- Trial name
- NCT01841021
- Testing
- Brentuximab vedotin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Cervical Cancer
A Clinical Study to Explore the Efficacy and Safety of Tislelizumab in Combination With Bevacizumab and Chemotherapy in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
Efficacy and safety of Tislelizumab combined with Bevacizumab and chemotherapy in patients with persistent, recurrent or metastatic cervical cancer.
- Trial name
- NCT05247619
- Testing
- Tislelizumab / Bevacizumab/Paclitaxel/Cisplatin/Carboplatin
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Zhejiang Cancer Hospital
Esophageal Cancer, Gastric Cancer
Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Cancer of the Stomach or Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005607
- Testing
- FOLFIRI regimen, fluorouracil, irinotecan hydrochloride
- Where
- 4 sites in United States
- Sponsor
- Robert H. Lurie Cancer Center
Glioblastoma
Abemaciclib + Pembrolizumab In Glioblastoma
This research study is studying a combination therapy as a possible treatment for recurrent glioblastoma (GBM), a brain tumor that is growing or progressing despite earlier treatment.
- Trial name
- NCT04118036
- Testing
- Pembrolizumab, Abemaciclib
- Where
- 2 sites in United States
- Sponsor
- Dana-Farber Cancer Institute
Malignant Glioma, High-Grade Gliomas
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
This is a draft, ClinicalTrials.gov-style example record for a first-in-human Phase 1 study evaluating locoregional administration of dual-targeting chimeric antigen receptor natural killer (CAR-NK) cells in adults with recurrent…
- Conditions
- Malignant Glioma, High-Grade Gliomas, Glioblastoma, Recurrent High-Grade Gliomas
- Trial name
- NCT07551336
- Testing
- Dual-target CAR-NK cells, Cyclophosphamide, Intracranial catheter/reservoir for locoregional delivery
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
Metastatic Skin Squamous Cell Carcinoma, Recurrent Skin Squamous Cell Carcinoma
Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer
This phase I trial studies how well cemiplimab before and after surgery works in treating patients with high risk cutaneous squamous cell cancer.
- Trial name
- NCT04428671
- Testing
- Cemiplimab, Radiation Therapy, Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Emory University
Melanoma (Skin), Unspecified Adult Solid Tumor, Protocol Specific
PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma
RATIONALE: PI-88 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I/II trial to study the effectiveness of PI-88 in treating patients who have an advanced malignancy (cancer) or stage IV melanoma.
- Trial name
- NCT00073892
- Testing
- PI-88
- Where
- 5 sites in United States, Australia
- Volunteers
- 44 people
- Sponsor
- Cellxpert Biotechnology Corp.
Recurrent Plasma Cell Myeloma
Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant
This phase II trial studies whether daratumumab and hyaluronidase-fihj and pomalidomide work in treating patients with multiple myeloma that has come back (relapsed) after stem cell transplant.
- Trial name
- NCT03622775
- Testing
- Daratumumab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia With FLT3/ITD Mutation, Recurrent Acute Myeloid Leukemia
Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia
This phase Ib/II trial studies the side effects and best dose of venetoclax in combination with quizartinib and how well they work in treating patients with acute myeloid leukemia that has come back or does not respond to…
- Conditions
- Acute Myeloid Leukemia With FLT3/ITD Mutation, Recurrent Acute Myeloid Leukemia, Refractory Acute Leukemia
- Trial name
- NCT03735875
- Testing
- Quizartinib, Venetoclax
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer Recurrent
Pilot Study of Whole Gland Salvage HDR Prostate Brachytherapy for Locally Recurrent Prostate Cancer
Radiation therapy is considered a standard treatment option for the management of localized prostate cancer. Among the 20-30% of patients who recur, there is no consensus on the optimal salvage therapy.
- Trial name
- NCT02560181
- Testing
- HDR brachytherapy
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Sunnybrook Health Sciences Centre
Breast Cancer Recurrent
Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer
POLAR is a phase III clinical trial, which will test the safety and efficacy of an investigational combination of drugs to learn whether the combination of drugs works for a specific cancer.
- Trial name
- POLAR (NCT03820830)
- Testing
- Palbociclib 125mg, Standard endocrine therapy
- Where
- 53 sites in Austria, France and 4 more
- Volunteers
- 405 people
- Sponsor
- ETOP IBCSG Partners Foundation
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)
Chronic myeloid leukemia (CML) is a hematopoietic neoplasm characterized by the reciprocal translocation t(9;22). The resulting oncoprotein, bcr-abl is an essential trigger for growth and survival of leukemic cells.
- Trial name
- NiloPost-STIM (NCT01774630)
- Testing
- Nilotinib
- Where
- 10 sites in France
- Volunteers
- 31 people
- Sponsor
- University Hospital, Bordeaux
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.